

With regard to the deficiencies of the previous reissue declaration, a supplemental reissue declaration^{*} is submitted herewith, which is believed to be free from these deficiencies.

With regard to the rejection on insufficient disclosure to teach how to make and use, only one utility is needed to support compound claims. Therefore, the utility disclosed in columns 9 and 10 is clearly sufficient to support the present compound claims, i.e., antitumor efficacy against L-210 leukemias transplanted in mice.

At the interview, the Examiner indicated that it would be sufficient to replace "anticancer" with "antitumor", and this has been accomplished by the above amendment.

In any event, the allegation of anticancer utility has been deleted from the specification and abstract, and therefore, it is apparent that the statement of utility in the present application is fully enabled.

Again, it must be emphasized that applicants are not disclosing or claiming a method of treating cancer, but are only disclosing a utility sufficient to support claimed compounds, and the instantly-disclosed utility clearly accomplishes this result.


No further issues remaining, allowance of this application is respectfully requested.

If, however, the Examiner is of the opinion that the present response does not overcome all objections and rejections, he is respectfully requested to telephone undersigned at the telephone number below to resolve any outstanding issues.

Respectfully submitted,

Tohru UEDA et al.

By


Matthew Jacob
Registration No. 25,154
Attorney for Applicants

MJ/acr
Washington, D.C.
Telephone (202) 371-8850
November 1, 1994

* Unexecuted, with executed copy to follow.